Mitochondrial-associated programmed-cell-death patterns for predicting the prognosis of non-small-cell lung cancer.
10.1007/s11684-024-1093-3
- Author:
Xueyan SHI
1
;
Sichong HAN
1
;
Guizhen WANG
1
;
Guangbiao ZHOU
2
Author Information
1. State Key Laboratory of Molecular Oncology & Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
2. State Key Laboratory of Molecular Oncology & Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. gbzhou@cicams.ac.cn.
- Publication Type:Journal Article
- Keywords:
NSCLC;
gene signature;
mitochondrial associated programmed cell death;
prognosis
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/pathology*;
Lung Neoplasms/pathology*;
Prognosis;
Male;
Female;
Nomograms;
Middle Aged;
Mitochondria/metabolism*;
Apoptosis/genetics*;
Mutation;
Biomarkers, Tumor/genetics*;
Aged
- From:
Frontiers of Medicine
2025;19(1):101-120
- CountryChina
- Language:English
-
Abstract:
Mitochondria are the convergence point of multiple pathways that trigger programmed cell death (PCD). Mitochondrial-associated PCD (mtPCD) is involved in the pathogenesis of several diseases. However, the role of mtPCD in the prognostic prediction of cancers including non-small-cell lung cancer (NSCLC) remains to be investigated. Here, 12 mtPCD patterns were analyzed in transcriptomics, genomics, and clinical data collected from 4 datasets containing 977 patients. A risk-score assessment system containing 18 genes was established. We found that NSCLC patients with a high-risk score had a poorer prognosis. A nomogram was constructed by incorporating the risk score with clinical features. The risk score was further associated with clinicopathological information, tumor-mutation frequency, and immunotherapy responses. NSCLC patients with a high risk score had more Treg cells infiltration. However, these patients had higher tumor-mutation burden scores and may be more sensitive to immunotherapy. Moreover, receptor-interacting serine/threonine protein kinase 2 (RIPK2) was selected from mtPCD gene model for validation. We found that RIPK2 exhibited oncogenic function, and its expression level was inversely associated with the overall survival of NSCLC. Taken together, our results indicated the accuracy and practicability of the mtPCD gene model and RIPK2 in predicting the prognosis of NSCLC.
